SELLAS Life Sciences Announces Positive WT1 Cancer Vaccine Clinical Results At The 13th International Conference Of The International Mesothelioma Interest Group /PRNewswire/ — SELLAS Life Sciences Group , a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancers and central nervous system diseases, today announced that results from a Phase 2 trial of the Company’s WT1 cancer vaccine in patients with malignant pleural mesothelioma were presented at the plenary session of the iMig 2016 Conference, being held .
